Y-Intercept (HK)’s Zenas BioPharma ZBIO Stock Holding History

Y-Intercept (HK)’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-17,332	Closed	-$440K	–	2189
2026 Q2	$440K	Buy	+17,332	New	+$345K	0.01%	1347

Other funds holding ZBIO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.3B AUM 33.78% 1-Year Est. Return

Y-Intercept (HK)'s ZBIO Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Zenas BioPharma (ZBIO) in Q3 2026, closing a stake of 17,332 shares — an estimated $440K sold.

Y-Intercept (HK) first reported a position in ZBIO in Q2 2026 and held it in 1 quarter. The position peaked at $440K in Q2 2026. 49 funds tracked by Wall St. Rank hold ZBIO as of Q3 2026.

Y-Intercept (HK) reported no remaining Zenas BioPharma position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 17,332 Zenas BioPharma shares in Q3 2026, an estimated $440K.
Y-Intercept (HK) first reported a position in Zenas BioPharma in Q2 2026 and held it in 1 quarter.
Y-Intercept (HK)'s Zenas BioPharma position peaked at $440K in Q2 2026.
49 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.